[Prolactinoma].
Prolactin-secreting tumours (prolactinomas) are benign neoplasms constituting about 40 percent of all pituitary tumours. The incidence of these tumours varies with age and sex, occurring most frequently in females between 20 and 40-years-old. The clinical symptoms of prolactinomas are menstrual dysfunction and galactorrhea in women and loss of libido and potency in men. Differential diagnosis of the disease should include the intake of various drugs, hypothyroidism, renal failure, liver cirrhosis, compression of the pituitary stalk by other pathologies, idiopathic hyperprolactinemia and other types of pituitary adenomas. The aims of treatment are to restore or to achieve eugonadism through the normalisation of hyperprolactinemia and control of tumour mass. Because of the established effectiveness in the majority of cases and small number of acceptable adverse effects, dopamine agonists are considered the drugs of choice. Transsphenoidal surgery remains an option when medical therapy is neither effective nor well tolerated. The authors review the diagnosis and management of prolactinomas, including progress made in recent years.
Krysiak
Robert
R
Klinika Chorób Wewnetrznych i Farmakologii Klinicznej, Katedry Farmakologii Slaskiego Uniwersytetu Medycznego w Katowicach. r.krysiak@interia.pl
Okopień
Bogusław
B
Marek
Bogdan
B
Szkróbka
Witold
W
D000328:Adult; D017677:Age Distribution; D015984:Causality; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007049:Iatrogenic Disease / Q000453:epidemiology; D008297:Male; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D015995:Prevalence; D015175:Prolactinoma / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D017678:Sex Distribution; D055815:Young Adult
D018491:Dopamine Agonists